These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 30076955

  • 1. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.
    Eur J Pharm Sci; 2018 Oct 15; 123():416-428. PubMed ID: 30076955
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J, Vallée F, Seelmann R, Sörgel F, Ruel M, LeBel M.
    Clin Pharmacol Ther; 1990 May 15; 47(5):618-28. PubMed ID: 2111750
    [Abstract] [Full Text] [Related]

  • 4. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
    Bulitta JB, Kinzig M, Landersdorfer CB, Holzgrabe U, Stephan U, Sörgel F.
    Antimicrob Agents Chemother; 2011 Jun 15; 55(6):2927-36. PubMed ID: 21402834
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Metabolism of fleroxacin in man.
    Sörgel F, Seelmann R, Naber K, Metz R, Muth P.
    J Antimicrob Chemother; 1988 Oct 15; 22 Suppl D():169-78. PubMed ID: 3144535
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E.
    Am J Med; 1993 Mar 22; 94(3A):70S-74S. PubMed ID: 8452185
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL, Vlahov V, Bacracheva N, Viachki I, Portmann R, Muirhead G, Stoeckel K, Weidekamm E.
    Antimicrob Agents Chemother; 1990 Dec 22; 34(12):2375-80. PubMed ID: 2128442
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.
    Schrenzel J, Cerruti F, Herrmann M, Leemann T, Weidekamm E, Portmann R, Hirschel B, Lew DP.
    Antimicrob Agents Chemother; 1994 Jun 22; 38(6):1219-24. PubMed ID: 8092817
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of fleroxacin determined by biological method.
    Verbist L, Van Hecken A, De Schepper P.
    J Chemother; 1989 Jul 22; 1(4 Suppl):572-3. PubMed ID: 16312537
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE, Frey FJ, Heizmann P, Brandt R, Weidekamm E.
    Antimicrob Agents Chemother; 1989 Mar 22; 33(3):373-81. PubMed ID: 2499248
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.